AU2018350975B2 - Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis - Google Patents

Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis Download PDF

Info

Publication number
AU2018350975B2
AU2018350975B2 AU2018350975A AU2018350975A AU2018350975B2 AU 2018350975 B2 AU2018350975 B2 AU 2018350975B2 AU 2018350975 A AU2018350975 A AU 2018350975A AU 2018350975 A AU2018350975 A AU 2018350975A AU 2018350975 B2 AU2018350975 B2 AU 2018350975B2
Authority
AU
Australia
Prior art keywords
data
evidence
variant
performance
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018350975A
Other languages
English (en)
Other versions
AU2018350975A1 (en
Inventor
Carlos L. Araya
Alexandre Colavin
Jason A. Reuter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invitae Corp
Original Assignee
Invitae Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitae Corp filed Critical Invitae Corp
Publication of AU2018350975A1 publication Critical patent/AU2018350975A1/en
Assigned to INVITAE CORPORATION reassignment INVITAE CORPORATION Request for Assignment Assignors: Jungla LLC.
Application granted granted Critical
Publication of AU2018350975B2 publication Critical patent/AU2018350975B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/211—Selection of the most significant subset of features
    • G06F18/2113—Selection of the most significant subset of features by ranking or filtering the set of features, e.g. using a measure of variance or of feature cross-correlation
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/217—Validation; Performance evaluation; Active pattern learning techniques
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/10—Ontologies; Annotations
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/01—Protocols
    • H04L67/10—Protocols in which an application is distributed across nodes in the network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/06—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for block-wise or stream coding, e.g. DES systems or RC4; Hash functions; Pseudorandom sequence generators
    • H04L9/0618—Block ciphers, i.e. encrypting groups of characters of a plain text message using fixed encryption transformation
    • H04L9/0637—Modes of operation, e.g. cipher block chaining [CBC], electronic codebook [ECB] or Galois/counter mode [GCM]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/06—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for block-wise or stream coding, e.g. DES systems or RC4; Hash functions; Pseudorandom sequence generators
    • H04L9/0643—Hash functions, e.g. MD5, SHA, HMAC or f9 MAC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/50—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols using hash chains, e.g. blockchains or hash trees

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Analytical Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Genetics & Genomics (AREA)
  • Software Systems (AREA)
  • Computer Security & Cryptography (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Power Engineering (AREA)
  • Computing Systems (AREA)
  • Mathematical Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
AU2018350975A 2017-10-17 2018-10-17 Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis Active AU2018350975B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573458P 2017-10-17 2017-10-17
US62/573,458 2017-10-17
PCT/US2018/056304 WO2019079464A1 (en) 2017-10-17 2018-10-17 PLATFORM OF MOLECULAR EVIDENCE FOR CONTINUOUS AND VERIFY OPTIMIZATION OF INTERPRETATION OF VARIANTS IN TESTS AND GENETIC ANALYZES

Publications (2)

Publication Number Publication Date
AU2018350975A1 AU2018350975A1 (en) 2020-05-07
AU2018350975B2 true AU2018350975B2 (en) 2023-11-23

Family

ID=66174641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018350975A Active AU2018350975B2 (en) 2017-10-17 2018-10-17 Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis

Country Status (10)

Country Link
US (4) US11462299B2 (enExample)
EP (1) EP3701534B1 (enExample)
JP (1) JP7258871B2 (enExample)
CN (1) CN112074909B (enExample)
AU (1) AU2018350975B2 (enExample)
BR (1) BR112020007449A2 (enExample)
CA (1) CA3079389A1 (enExample)
IL (1) IL274001A (enExample)
MX (1) MX2020003709A (enExample)
WO (1) WO2019079464A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701534B1 (en) 2017-10-17 2024-04-10 Invitae Corporation Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
US10959277B2 (en) * 2019-04-01 2021-03-23 T-Mobile Usa, Inc. Mobile device network performance restoration and improvement
US10764062B2 (en) * 2019-06-03 2020-09-01 Alibaba Group Holding Limited Blockchain ledger compression
CN110602162B (zh) * 2019-08-06 2022-11-01 苏州龙信信息科技有限公司 终端取证方法、装置、设备和存储介质
CN110957006B (zh) * 2019-12-14 2023-08-11 杭州联川基因诊断技术有限公司 一种brca1/2基因变异的解读方法
CN112489812B (zh) * 2020-11-30 2021-07-06 北京华彬立成科技有限公司 药物开发分析方法、装置、电子设备和存储介质
US20230351337A1 (en) * 2022-04-29 2023-11-02 Bank Of America Corporation Generating and securing digital checks using distributed ledger and embedded chip methods
US12211039B2 (en) * 2022-09-20 2025-01-28 Veiovia Limited Externally validated proof of work for appending a block record to a blockchain with a data broker server
US11652650B1 (en) * 2022-09-20 2023-05-16 Veiovia Limited Externally validated proof of work for appending a block record to a blockchain with a commitment database server
US12216661B2 (en) 2022-09-20 2025-02-04 Veiovia Ltd. Externally validated proof of work for appending a block record to a blockchain with a mining node
WO2025115360A1 (ja) * 2023-11-30 2025-06-05 富士フイルム株式会社 木構造生成方法、情報処理装置、情報処理システム、及び木構造生成プログラム
CN119719955B (zh) * 2024-12-17 2025-09-05 四川大学华西医院 一种基于贝叶斯模型的证据优化方法、装置、计算机设备及存储介质

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027085A1 (en) * 2013-08-22 2015-02-26 Genomoncology, Llc Computer-based systems and methods for analyzing genomes based on discrete data structures corresponding to genetic variants therein
WO2016154584A1 (en) * 2015-03-26 2016-09-29 Quest Diagnostics Investments Incorporated Alignment and variant sequencing analysis pipeline
US20160306923A1 (en) * 2013-01-17 2016-10-20 Edico Genome, Inc. Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
WO2016172464A1 (en) * 2015-04-22 2016-10-27 Genepeeks, Inc. Device, system and method for assessing risk of variant-specific gene dysfunction

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972693A (en) 1995-10-24 1999-10-26 Curagen Corporation Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US5780236A (en) 1996-11-18 1998-07-14 Wisconsin Alumni Research Foundation Method for identifying mutants and molecules
US6949692B2 (en) 1996-11-18 2005-09-27 Wisconsin Alumni Research Foundation Method for identifying mutants and molecules
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20060223058A1 (en) * 2005-04-01 2006-10-05 Perlegen Sciences, Inc. In vitro association studies
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
WO2008033239A2 (en) 2006-09-11 2008-03-20 Applera Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
KR101325736B1 (ko) * 2010-10-27 2013-11-08 삼성에스디에스 주식회사 바이오 마커 추출 장치 및 방법
US20130338012A1 (en) 2010-11-18 2013-12-19 Illumina Inc. Genetic risk factors of sick sinus syndrome
WO2012155148A2 (en) 2011-05-12 2012-11-15 University Of Utah Research Foundation Predicting gene variant pathogenicity
US8718950B2 (en) * 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
US9773091B2 (en) * 2011-10-31 2017-09-26 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US9235686B2 (en) 2012-01-06 2016-01-12 Molecular Health Gmbh Systems and methods for using adverse event data to predict potential side effects
US20140089009A1 (en) * 2012-09-27 2014-03-27 Wobblebase, Inc. Method for Personal Genome Data Management
SG11201505969XA (en) * 2013-01-31 2015-08-28 Codexis Inc Methods, systems, and software for identifying bio-molecules with interacting components
US20160048633A1 (en) * 2013-03-15 2016-02-18 Cypher Genomics, Inc. Systems and methods for genomic variant annotation
WO2014151764A2 (en) * 2013-03-15 2014-09-25 Veracyte, Inc. Methods and compositions for classification of samples
US10235496B2 (en) * 2013-03-15 2019-03-19 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
JP6566484B2 (ja) * 2013-06-14 2019-08-28 キージーン ナムローゼ フェンノートシャップ 表現形質改善のための制御された戦略
US20150025861A1 (en) * 2013-07-17 2015-01-22 The Johns Hopkins University Genetic screening computing systems and methods
US20160314245A1 (en) 2014-06-17 2016-10-27 Genepeeks, Inc. Device, system and method for assessing risk of variant-specific gene dysfunction
CN106796620A (zh) * 2014-06-30 2017-05-31 凯杰雷德伍德城公司 用于解释和报告基于序列的基因测试的方法和系统
EP3189619B1 (en) * 2014-09-03 2021-02-17 NantOmics, LLC Device, method and computer program product for synthetic genomic variant-based secure transaction
US10185803B2 (en) 2015-06-15 2019-01-22 Deep Genomics Incorporated Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network
EP3433781A4 (en) * 2016-03-21 2019-12-04 Human Longevity, Inc. GENOMIC, METABOLOMIC AND MICROBIOMICAL RESEARCH ENGINE
EP3701534B1 (en) 2017-10-17 2024-04-10 Invitae Corporation Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
US10978196B2 (en) * 2018-10-17 2021-04-13 Tempus Labs, Inc. Data-based mental disorder research and treatment systems and methods
US20200121715A1 (en) 2018-10-20 2020-04-23 MC Technology Holdings, LLC Composition comprising aqueous medium with reduced size water clusters to improve bioavailability of the aqueous medium and methods for making and using the compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160306923A1 (en) * 2013-01-17 2016-10-20 Edico Genome, Inc. Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
WO2015027085A1 (en) * 2013-08-22 2015-02-26 Genomoncology, Llc Computer-based systems and methods for analyzing genomes based on discrete data structures corresponding to genetic variants therein
WO2016154584A1 (en) * 2015-03-26 2016-09-29 Quest Diagnostics Investments Incorporated Alignment and variant sequencing analysis pipeline
WO2016172464A1 (en) * 2015-04-22 2016-10-27 Genepeeks, Inc. Device, system and method for assessing risk of variant-specific gene dysfunction

Also Published As

Publication number Publication date
US20230117854A1 (en) 2023-04-20
MX2020003709A (es) 2020-07-22
CN112074909A (zh) 2020-12-11
US20200251179A1 (en) 2020-08-06
US20190189246A1 (en) 2019-06-20
US11798651B2 (en) 2023-10-24
AU2018350975A1 (en) 2020-05-07
US11462299B2 (en) 2022-10-04
EP3701534A4 (en) 2021-08-04
JP2020537795A (ja) 2020-12-24
BR112020007449A2 (pt) 2020-10-20
US12136472B2 (en) 2024-11-05
CA3079389A1 (en) 2019-04-25
US20240006021A1 (en) 2024-01-04
IL274001A (en) 2020-05-31
JP7258871B2 (ja) 2023-04-17
EP3701534C0 (en) 2024-04-10
EP3701534B1 (en) 2024-04-10
CN112074909B (zh) 2024-03-19
EP3701534A1 (en) 2020-09-02
WO2019079464A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
US12136472B2 (en) Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
US10867702B2 (en) Individual and cohort pharmacological phenotype prediction platform
Zhang et al. Clinical interpretation of sequence variants
Smith et al. Classification of genes: standardized clinical validity assessment of gene–disease associations aids diagnostic exome analysis and reclassifications
US20220183571A1 (en) Predicting fractional flow reserve from electrocardiograms and patient records
Register-Brown et al. Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis
Ko et al. GWAS of longitudinal trajectories at biobank scale
KR20090105921A (ko) 유전자 분석 시스템 및 방법
Bascom et al. Heritable disorders of connective tissue: description of a data repository and initial cohort characterization
Garringer et al. Hearing impairment susceptibility in elderly men and the DFNA18 locus
Kobayashi et al. Clinical variant reclassification in hereditary disease genetic testing
Zhou et al. A phenome-wide scan reveals convergence of common and rare variant associations
Day et al. Association of acquired and heritable factors with intergenerational differences in age at symptomatic onset of Alzheimer disease between offspring and parents with dementia
Song et al. Polygenic risk scores and twin concordance for schizophrenia and bipolar disorder
Feng et al. Psychiatric manifestations of rare variation in medically actionable genes: a PheWAS approach
Hou et al. Potential Biomarkers for Predicting the Risk of Developing Into Long COVID After COVID‐19 Infection
Chakraborty et al. A quantitative trait GWAS on lens thickness identifies novel risk loci on PTPRM in the narrow angle individuals susceptible to PACG
Kang et al. Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits
Hu et al. PAD-associated genetic variants are more strongly associated with surgical intervention than premature onset
Huerta Human Phenotype Ontology-driven Comparison of Whole Exome Sequencing Findings in a Tertiary Center
EP4634927A1 (en) Systems and methods for patient-specific treatment recommendation optimized with multistage machine learning
Jr et al. Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits
Ruderfer Genome-ide association stud of treatment-resistant depression: shared biolog ith metabolic traits
Dattani downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INVITAE CORPORATION

Free format text: FORMER APPLICANT(S): JUNGLA LLC.

FGA Letters patent sealed or granted (standard patent)